甲磺酸倍他司汀与尼莫地平治疗神经性耳鸣疗效对比  

Efficacy of Betahistine Mesilate and Nimodipine for Treating Nervous Tinnitus in 34 Cases

作　　者：侯莉 王琦 

机构地区：[1]四川省德阳市妇幼保健院,四川德阳618000

出　　处：《中国药业》2015年第12期42-43,共2页China Pharmaceuticals

摘　　要：目的观察并对比甲磺酸倍他司汀与尼莫地平治疗神经性耳鸣的临床疗效。方法将医院2013年12月至2014年12月收治的68例耳鸣患者分为对照组和治疗组,各34例,对照组患者采用尼莫地平治疗,治疗组患者采用甲磺酸倍他司汀治疗。结果治疗后,两组患者耳鸣症状均得到有效改善,且治疗组改善更显著(P<0.05);治疗组患者耳鸣症状评分显著低于对照组(P<0.05);治疗组患者瞬态诱发性耳声发射(TEOAE)有效引出率显著高于对照组(P<0.05);两组患者在治疗过程中均出现了不良反应,但治疗组不良反应发生率明显低于对照组(P<0.05)。结论甲磺酸倍他司汀治疗神经性耳鸣的临床疗效比尼莫地平更确切,能促进耳蜗功能的恢复,且安全性高,值得临床推广。Objective To observe the clinical efficacy of betahistine mesilate and nimodipine in the treatment of nervous tinni-tus. Methods 68 patients with nervous tinnitus in the hospital from December 2013 to December 2014 were divided into the treatment group and the control group,34 cases each. The control group was treated with nimodipine,while the treatment group used the betahis-tine mesilate therapy. Results The tinnitus symptom after treatment in the two groups was effectively improved,moreover the improve-ment of the treatment group was more significant（ P 〈 0. 05）;the scores of tinnitus symptom in the treatment group were significantly lower than those in the control group（ P 〈 0. 05）;the effective elicitation rate of transient evoked otoacoustic emission（TEOAE）in the treatment group was significantly higher than that in the control group;the adverse reactions appeared during the treatment process in the two groups,but the occurrence rate of adverse reaction in the treatment group was significantly lower than that in the control group,the difference was statistically significant（ P 〈 0. 05）. Conclusion Betahistine mesilate has definite clinical effect for treating nervous tinnitus,can promote the recovery of cochlear function with high safety and deserves to be clinically promoted.

关 键 词：甲磺酸倍他司汀 神经性耳鸣 瞬态诱发性耳声发射 

分 类 号：R969.4[医药卫生—药理学] R972.4[医药卫生—药学]